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Ovarian cancer is the fifth most common cause of cancer death among women in Europe 
(1), and high-grade serous ovarian carcinoma is the most common subtype of ovarian 
cancer (2). Over the last decades, research has uncovered considerable new information 
about the biology of high-grade serous ovarian carcinoma (HGSC). As of today, this has 
not yet translated into a significantly improved prognosis for patients, though the latest 
studies on PARP-inhibitors have brought hope that this may soon change (ibid.). High-
grade serous ovarian carcinoma is an interesting disease to study as outcomes for 
patients are quite diverse, i.e. there is considerable variation in the length of overall 
survival and/or relapse-free survival. That is why it is of great interest to construct a 
sizable cohort of HGSC patients, that combines patients’ tumor samples and clinical data 
in order to study groups with different disease outcomes and varying responses to 
treatment and try to find clinical as well as biological factors that can explain these 
differences. 
This report describes how a retrospective cohort of HGSC patients is being built in Olli 
Carpén’s research group at the Department of Pathology within the Faculty of Medicine 
at the University of Helsinki. Tissue samples were obtained from Helsinki Biobank, and 
clinical data was retrieved from several electronic data bases as well as paper archives. 
Biobank data scientist Jani Salmi has analyzed the clinical data to identify subgroups of 
patients using machine learning technology (Tools for digital phenotyping of disease 
entities -project). My work within the cohort formation has primarily been to collect 
clinical data from patients’ archived paper files.  
The next chapter will introduce the topic of ovarian cancer in general and the subtype 





2 High-grade serous carcinoma as a subtype of ovarian carcinoma 
The research project focuses on high-grade serous ovarian carcinoma as the most 
common subtype of epithelial ovarian cancer. Past research has shown that ovarian 
cancer subtypes differ substantially from each other regarding their biology, and today 
those subtypes are considered different diseases rather than subtypes of the same 
disease. (3)   
2.1 Ovarian cancer classification 
There is a great variety of ovarian tumors. The “WHO Classification of Tumours of 
Female Reproductive Organs” from 2014 provides a detailed classification of the 
different ovarian tumor types. The classification has changed over time and the newest 
version reflects advances in molecular biology and pathological research which have led 
to a better understanding of the disease subtypes. (4) Firstly, one can distinguish 
epithelial tumors from non-epithelial tumors. Non-epithelial tumors include categories 
such as sex cord-stromal tumors or germ cell tumors. 
Secondly, within the epithelial tumor category, the WHO classification distinguishes the 
following subtypes: serous, mucinous, endometrioid, clear cell, Brenner, seromucinous, 
and undifferentiated. Of the first six epithelial tumor subtypes the classification lists 
benign, borderline (intermediate) and malignant variants. By definition the 
undifferentiated category contains only undifferentiated carcinoma. There is one 
malignant variant of each tumor subtype mentioned, with the exception of serous 
tumors, which have two malignant forms: low-grade and high-grade serous carcinoma. 
Serous carcinoma was formerly considered a continuum ranging from grade 1 to grade 
3. However, subsequent research found that they are in fact biologically very different 
and are today called high-grade serous carcinoma (HGSC), which accounts for most of 
the formerly grade 2 and 3 serous tumors, and low-grade serous carcinoma (LGSC), 
corresponding to most of the formerly grade 1 tumors. (4) According to accumulated 
research results, LGSCs evolve through a BRAF- or KRAS-mutation, whereas HGSCs 
evolve through a p53-mutation (5). Though they are now thought to be two distinct 
diseases, very rarely a low-grade serous carcinoma can develop into a high-grade serous 




About 90% of all malignant ovarian tumors are epithelial tumors, i.e. carcinomas. Of 
these, over two-thirds are high-grade serous carcinomas (6). Table 1 summarizes the 
different ovarian carcinoma subtypes and their relative frequencies.  
Table 1: Types of ovarian carcinoma, percentages from Prat’s review article (6) 
Ovarian carcinoma subtype % of ovarian carcinomas 
High-grade serous carcinoma (HGSC) 70% 
Endometrioid carcinoma (EC) 10% 
Clear cell carcinoma (CCC) 10% 
Low-grade serous carcinoma (LGSC) <5% 
Mucinous carcinoma (MC)  3% 
Others: malignant Brenner tumour, seromucinous 




As Mutch points out “primary fallopian tube cancer and primary peritoneal cancer are 
rare malignancies but share many clinical and morphologic similarities with HGSC” (7). 
Additionally, the WHO classification states that HGSOC can be seen as an “amalgamation 
of primary (extra-uterine) ̀ pelvic high-grade serous carcinomas`” as they may arise from 
the ovary, the fallopian tube or the peritoneum (4). In this sense the word “ovarian” can 
be somewhat misleading, as HGSC can present without involvement of the ovaries (see 
below the discussion of the etiology of HGSC). For this reason, the terms high-grade 
serous ovarian carcinoma (HGSOC) and high-grade serous carcinoma (HGSC) are used 
synonymously in the following text and we also included such patients in our study, 
whose disease did not affect the ovaries.  
 
2.2 Epidemiology 
Ovarian cancer is the fifth most common cause of cancer death among females in 
Europe (1). It is estimated that worldwide 225 000 women are diagnosed with ovarian 
carcinoma every year, most of which are HGSC, and 140 000 die of their disease (4). In 





2.3 Etiology  
There is some evidence to suggest that lower ovarian cancer risk correlates with later 
age at menarche, younger age at menopause, using oral contraceptives and parity – all 
factors leading to a lower number of menstrual cycles over a lifetime. Estrogen hormone 
therapy after menopause seems to increase ovarian cancer risk. However, many of these 
studies looked at ovarian cancer in general and did not distinguish between the different 
histotypes. (4) 
Genetically, genomic instability and DNA copy number variations are typical in HGSC, 
but there are not many consistently mutated genes.(3) The p53 gene is almost always 
abnormal, and there is a defect in the homologous recombination pathway for DNA 
repair in approximately 50 percent of HGSCs. (9) Many of these are due to BRCA1 or 2 
germline or somatic mutation, or BRCA1 promoter methylation, but other defects in the 
pathway also lead to HR deficiency, such as high expression of EMSY, which codes for a 
protein binding to BRCA2 inactivating it (10). Knowledge of HR pathway deficiency is 
important as these patients may benefit from treatment with PARP-inhibitors (see 
chapter 2.7).  
HGSC was long believed to develop from the surface epithelium of the ovaries, but 
researchers studying the fallopian tubes of patients with high risk mutations, who had 
their tubes and ovaries removed in order to prevent ovarian carcinoma, found serous 
tubal intraepithelial carcinomas (STIC) and tubal carcinomas, suggesting that the 
fimbriae of the fallopian tube could be the site of origin. (3) Subsequent research also 
showed that precursor STICs contain the same genetic alterations as later tumors: 
Labidi-Galy and colleagues suggest that it takes about 7 years from a STIC to the 
development of HGSC, which then spreads quickly (11). Other studies suggest that there 
may be some HGSC tumors which arise from precursors in the fallopian tubes, and 







2.4 Clinical symptoms, diagnosis, screening, prevention  
The average age at HGSC diagnosis is about 63 years (4), e.g. Peres and colleagues report 
an average age at diagnosis of 61.2 years with a standard deviation of 11.6 years.  Their 
study of patients in the United States also shows the wide age range of HGSC patients; 
3% of patients were aged 20-39 years at diagnosis and 5.5% were 80-84 years. (12) 
Most patients are diagnosed with advanced disease, when the carcinoma has already 
spread to the abdominal cavity beyond pelvis, which corresponds to stage III or IV (see 
chapter 2.6 for staging and chapter 2.8, table 3, for stage at diagnosis). The reason for 
this is that the clinical symptoms are rather nonspecific, and may include gastrointestinal 
symptoms such as nausea, early satiety, anorexia, constipation, tenesmus, or bloating, 
as well as increased urinary frequency, back pain, stomach ache, fatigue, difficulty 
breathing, or bleeding. (4, 13) 
Diagnostic studies include serum tumor marker CA-125 and HE4 levels as well as imaging 
studies, e.g. ultrasound, CT, MRI or PET-CT. Cancer antigen 125 (CA-125) is usually 
elevated in HGSC; median levels are 500-1000 U/ml in the setting of advanced disease 
patients. Imaging reveals complex, hypervascular masses in the pelvis (especially 
adnexa), ascites, or omental or peritoneal nodules (4). The final diagnosis is usually made 
based on a histologic sample, e.g. tumor samples from diagnostic or debulking surgery 
or biopsy. Cytologic samples from ascites or pleural effusions also assist in diagnosis. 
(14) 
Because of the delayed diagnosis of HGSC, and ovarian cancer in general, the possibility 
of curative treatment becomes very rare (compared to early stage disease). Therefore, 
considerable effort has been devoted to developing effective screening methods. Serum 
CA-125 levels alone or combined with transvaginal ultrasound and/or additional 
markers such as HE4, MMP-7 or CA-72-4 have been tested as potential screening tools. 
(15) Circulating tumor cells and cell-free DNA could be a means for early diagnosis, 
monitoring disease progression, and even for identifying clinically actionable alterations 
in HGSC (16). The use of liquid biopsies for ovarian cancer screening and disease 
monitoring is being studied (17), however, none of these measures has yet met the 




for mass screening. Research efforts continue, and there will hopefully be an effective 
screening method in the future.  
Preventive surgery is recommended for known high risk groups, i.e. carriers of BRCA1 or 
BRCA2 mutations. Germline BRCA-mutations are associated with a considerably higher 
risk of ovarian cancer; there is a 20-65% lifetime risk for patients with a BRCA1 mutation 
and 11-37% for patients with a BRCA2 mutation. Almost all of the BRCA-associated 
ovarian cancers are HGSCs. (4) The Finnish Society of Obstetrics and Gynecology 
recommends the excision of fallopian tubes and ovaries for BRCA1 carriers by the age of 
40 and for BRCA2 carriers by the age of 45 (18).   
 
2.5 Morphology and immunohistochemistry 
The WHO classification defines HGSC morphology as “a carcinoma composed of 
epithelial cells displaying papillary, glandular (often slit-like) and solid patterns with 
high-grade nuclear atypia” (3). 
Immunohistochemical staining is often used by pathologists to verify a morphologic 
diagnosis. HGSC is characterized by positive staining for the marker WT1 and by 
abnormal TP53 staining. Aberrant TP53 staining can mean either its complete absence, 
or diffuse overexpression. However, there is no single antibody, or combination of 
antibodies, that can define this histotype with 100% accuracy. In Köbel et al.’s study, 
96.7% of HGSC cases stained positive for WT1 and 93.9% of HGSC cases showed aberrant 
TP53 staining. 91.7% of HGSC cases showed both WT1 positivity and TP53 aberrancy, 
while there were only very few cases that showed those two characteristics while not 
being HGSC (less than 1% of cases with these staining characteristics). (19) 
According to a simplified algorithm one could first test for WT1 staining, positive staining 
meaning that the histotype is probably either low-grade or high-grade serous, and 
negative staining meaning it is more likely to be clear cell, mucinous or endometrioid. 
The pattern of TP53 staining then differs between low-grade and high-grade serous 




In their recent paper Köbel and colleagues test a third version of their “Calculator of 
Ovarian carcinoma Subtype/ histotype Probability” (COSPv3). They conclude that the 
integration of IHC-stains can improve histotyping, however one cannot (yet) rely on it 
alone, since in 7% of cases COSPv3´s predictions were discordant with the benchmark 
integrated histotype, which was based on morphological and IHC information. (20) 
 
2.6 Staging 
Cancer staging is an important tool that helps to understand the patient’s condition, 
allows for outcome prediction to a certain degree and assists in choosing the 
appropriate treatment. For ovarian cancer, the staging classification of the International 
Federation of Gynecology and Obstetrics (FIGO), first published in 1973, is widely used1. 
(7) It was also used in the clinical reports assessed in this study and therefore it will be 
presented here shortly. The classification has been revised over the years and the latest 
version is from 2014, which is summarized in table 2. As pointed out later, we used the 
2014 classification and re-staged patients accordingly based on medical reports. 
HGSC is characterized by spread within the peritoneal cavity, which has no physical 
barriers to metastasis, which is believed to enable spreading of the disease to distant 
sites within the cavity (21). FIGO stage I indicates that the tumor is confined to the 
ovaries; in stage II it has spread within the pelvis, but not above the pelvic brim. Stage 
III means that the disease has spread to the peritoneal cavity outside the pelvis and/or 
to the retroperitoneal lymph nodes. Stage IV disease means intraparenchymal hepatic 
or splenic metastasis, or spread of the disease to distant sites outside the peritoneal 
cavity, such as lungs or the umbilicus. 
Staging in ovarian cancer is based on the staging surgery, radiographic images, and 
histologic results from washings, ascites, pleural effusions and biopsies. Patients with 
FIGO stage I and II disease, where cancer is confined to the pelvis, have a much better 
 
1 Also the TNM staging is used, see table 1 in Mutch’s paper for the Figo staging system and the 
corresponding TNM (7). The German current care guideline for ovarian cancer (S3-Leitlinie Diagnostik, 
Therapie und Nachsorge maligner Ovarialtumoren, p. 66) states that pathologists should always report 




prognosis than patients with spread outside of the pelvis (stage III or IV). Unfortunately, 
most HGSC are stage III or IV at diagnosis (see chapter 2.8).  
Table 2: The 2014 FIGO Ovarian Cancer Staging as outlined by the Society of Gynecologic 
Oncology (22) 
STAGE I: Tumor confined to ovaries 
IA  Tumor limited to 1 ovary, capsule intact, no tumor on surface, negative 
washings. 
IB Tumor involves both ovaries otherwise like IA. 
IC Tumor limited to 1 or both ovaries 
 IC1 Surgical spill 
 IC2 Capsule rupture before surgery or tumor on ovarian surface 
 IC3 Malignant cells in the ascites or peritoneal washings 
STAGE II: Tumor involves 1 or both ovaries with pelvic extension (below the pelvic brim) or 
primary peritoneal cancer 
IIA Extension and/or implant on uterus and/or Fallopian tubes 
IIB Extension to other pelvic intraperitoneal tissues 
STAGE III: Tumor involves 1 or both ovaries with cytologically or histologically confirmed 
spread to the peritoneum outside the pelvis and/or metastasis to the retroperitoneal 
lymph nodes 
IIIA Positive retroperitoneal lymph nodes and /or microscopic metastasis 
beyond the pelvis 
 IIIA1 Positive retroperitoneal lymph nodes only 
IIIA1(i) Metastasis ≤ 10 mm 
IIIA1(ii) Metastasis > 10 mm 
 IIIA2 Microscopic, extrapelvic (above the brim) peritoneal involvement ± 
positive retroperitoneal lymph nodes 
IIIB Macroscopic, extrapelvic, peritoneal metastasis ≤ 2 cm ± positive 
retroperitoneal lymph nodes. Includes extension to capsule of 
liver/spleen. 
IIIC Macroscopic, extrapelvic, peritoneal metastasis > 2 cm ± positive 
retroperitoneal lymph nodes. Includes extension to capsule of 
liver/spleen. 
STAGE IV: Distant metastasis excluding peritoneal metastasis 
IVA Pleural effusion with positive cytology 
IVB Hepatic and/or splenic parenchymal metastasis, metastasis to 
extraabdominal organs (including inguinal lymph nodes and lymph nodes 
outside of the abdominal cavity) 
 
As pointed out earlier (see chapter 2.1) HGSC can also originate from the fallopian tubes 
or the peritoneum. To account for this, the FIGO staging protocol also exists as a version 
which includes tubal origin as an alternative in the early stages, i.e. every time the ovary 




Mutch’s review article for that version of the FIGO classification (7)). Primary peritoneal 
cancer is staged starting from stage II in both versions.    
2.7 Treatment 
After diagnosis one has to decide whether it is beneficial for the patient to undergo 
primary debulking surgery2. Primary means that the surgery takes place before any 
possible chemotherapy and debulking refers to a surgery that tries to resect all tumor 
tissue. Debulking surgery usually removes the uterus, adnexa, omentum, ascites and 
when indicated, the appendix, segments of the intestine, peritoneum, and the 
parenchyma of any other affected organs. Biopsies of the abdominal cavity as well as 
cytological samples of ascites and washings are also components of the so-called 
staging-surgery protocol. Resection of the pelvic and para-aortic lymph nodes is done 
depending on the circumstances, e.g. it is recommended for stage I and II disease in 
general, but for stage III and IV only in cases of bulky lymph node metastasis (for more 
details see for example the KELPO care guidelines of the Finnish Society of Obstetrics 
and Gynaecology). (18)3 
One alternative to primary debulking surgery is neoadjuvant chemotherapy (NACT), with 
later interval debulking surgery if reasonable. The question of optimal timing for the 
debulking surgery is controversial and has been studied intensively. The Current 
Guidelines of the German Guideline Program in Oncology conclude that there is no 
advantage to NACT and interval surgery as compared to post-surgery chemotherapy, 
and therefore recommend primary debulking surgery followed by chemotherapy. (5) 
The Finnish guidelines recommend 3 to 4 cycles of NACT followed by interval surgery 
when, according to examinations such CT scan, it is predicted that primary surgery 
would not lead to a major cytoreduction. (18) 
 
2 This chapter relies mainly on information taken from the Finnish and German Care Guidelines for the 
treatment of ovarian carcinoma . Most of the treatment is identical for the different histotypes of 
ovarian carcinoma, e.g. surgery treatment and standard chemotherapy.  
3 The Finnish Medical Society Duodecim has withdrawn its Current Care Guideline (i.e. “Käypä Hoito”) 
for Ovarian Cancer from 14th June 2019, the society announced that they will not continue to update 
the guideline, the last update dates back to 2012. (16) However, the Finnish Society of Obstetrics and 
Gynaecology publishes so-called KELPO care guidelines for the treatment of epithelial ovarian cancer on 




Based on research results, it is also recommended that the surgery is performed by an 
experienced gynecologic oncologist, and in some ultra-radical debulking surgeries, in co-
operation with surgeons from other specialties, such as gastrointestinal surgeons. (5, 
18) 
One alternative to the conventional surgical technique is the application of a 
hyperthermic chemotherapeutic drug directly into the abdominal cavity in connection 
with the surgery, the so called hyperthermic intraperitoneal chemotherapy (HIPEC). 
Thus far, there is no strong evidence that justifies the use of HIPEC in the treatment of 
ovarian carcinoma (5); the Finnish guidelines recommend its use only in the context of 
clinical trials (18)4.  
Chemotherapeutic treatment is always recommended for HGSC patients, independent 
of stage5. The standard recommendation is 6 cycles of intravenous carboplatin6 (dose 
AUC 5) and paclitaxel7 (dose 175 mg/m2), infused over 3 hours, with 3 weeks between 
cycles (5). Paclitaxel can also be given weekly and carboplatin every three weeks. For 
patients with a poor functional status, considerable comorbidity, or early stage disease, 
monotherapy with carboplatin can also be considered.  
Bevacizumab, a humanized monoclonal antibody that inhibits angiogenesis by targeting 
and blocking vascular endothelial growth factor (VEGF) (25), can be added to first line 
chemotherapy in advanced disease. The Finnish guidelines recommend it for stage IIIb 
and IIIc disease with suboptimal surgery outcome, meaning residual tumor greater than 
1 cm, or for stage IV disease (18). This drug has been shown to prolong progression free 
survival, but an improvement in overall survival could be shown only for subgroups, e.g. 
high tumor load or stage IV disease (5).  
 
4 The same recommendation is given for intraperitoneal chemotherapy, meaning that the cytostatic 
drug is applied to the peritoneal cavity and not intravenously.  
5 Only patients with FIGO stage 1A well differentiated ovarian carcinoma, who had complete staging 
surgery, should not receive adjuvant chemotherapy. But for poorly differentiated carcinoma, e.g. HGSC, 
it is always recommended. (5, 18) 
6 Carboplatin is a platinum-based drug, the parent compound is cisplatin. Its mechanism of action as an 
anti-cancer drug is described as following: “Carboplatin undergoes activation inside cells and forms 
reactive platinum complexes that cause the intra- and inter-strand cross-linkage of DNA molecules 
within the cell. This modifies the DNA structure and inhibits DNA synthesis.”(23) 
7 Paklitaxel is an anti-mitotic drug, it hyper-stabilizes the structure of microtubules and therefore 
prevents the cell in using its cytoskeleton in a dynamic way. It might also induce apoptosis in cancer cells 




Patients with HGSC often respond to platinum-based therapy (9). However, most 
patients relapse at some point, and the relapsed disease is not considered curable in 
most cases. However, patients can live with the disease for a variable length of time. 
Treatment of relapsed disease is different for platinum-sensitive and platinum-resistant 
tumors. In addition to paclitaxel and carboplatin, drugs such as topotecan, gemcitabine, 
PEGylated liposomal doxorubicin, epirubicin, and etoposide can be used in combination 
or as single agents, depending on the circumstances. For platinum-sensitive disease, the 
treatment goal is prolongation of progression-free survival and overall survival; in a 
platinum-resistant disease relapse the aim is preservation of quality-of-life and 
symptom management. (5) 
For many years there was no major progress in the treatment of HGSC, but in recent 
years the addition of PARP-inhibitors to the treatment of ovarian carcinoma has been 
studied and has brought new hope for at least some patients. Poly-ADP-ribose- 
polymerases (PARP) are proteins which are activated by DNA damage and enable the 
repair of single-strand DNA breaks. In the presence of a PARP-inhibitors, the single-
strand break repair pathway is blocked, which results in double-strand breaks. The 
double-strand breaks would be repaired by the homologous recombination (HR) 
pathway, but this pathway is not functioning in, for example, BRCA-mutated or 
otherwise HR-deficient cells, which eventually leads to cell death.(26) Moore and 
colleagues reported the first results of the SOLO1 trial, a phase 3 trial studying the 
efficacy of PARP-inhibitor olaparib used as maintenance therapy after surgery and 
platinum-based chemotherapy in patients with newly diagnosed FIGO-stage III or IV 
disease (high-grade serous or endometrioid ovarian cancer, fallopian-tube cancer or 
primary peritoneal cancer), who had a BRCA1 and/or BRCA2 mutation and who had 
complete or partial response to the platinum-based chemotherapy. They found a 
substantial benefit of olaparib maintenance therapy, e.g. 4 years after first-line 
chemotherapy 53% of the patients of the olaparib group were progression-free, 
compared to 11% of the placebo group. These findings were the first sign of a major 
improvement in the therapy of high-grade serous ovarian cancer in a long time. (27)  




estimated to be found in up to 25% of HGSC patients8 (29), the potential utility for 
patients with a deficiency in homologous recombination (HRD carcinomas) due to 
another reason such as BRCA1/2 somatic mutation, BRCA1 promotor methylation or 
EMSY amplification, is compelling (10, 30). Recent research findings suggest, that PARP-
inhibitors work well as maintenance therapy following first line platinum-based 
chemotherapy for patients, who respond to platinum-based chemotherapy, which in 
turn can be seen as a clinical correlate for HRD (28, 31, 32). 
On the other hand, the response rate of patients with BRCA1/2 mutations to PARP-
inhibitors is far less than 100 percent, which may be due to a restored HR pathway or 
another resistance mechanism (2); hopefully future research will clarify how to identify 
specific patients who would benefit from PARP-inhibitors. (32, 33) 
Immunotherapy is currently utilized with success in some cancers, such as melanoma, 
but has not yet been successful in the treatment of ovarian carcinoma, despite the fact 
that tumor infiltration by T-cells has long been a recognized predictor of outcome. One 
reason could be the heterogeneity of immunological microenvironments within 
different metastases, as Jiménez-Sáchez and colleagues show in their interesting case 
study. (34) However, the potential of immunological therapies, also in combination with 
other therapies, is a subject of on-going research. 
 
2.8 Prognostic factors 
The most important prognostic factor for disease outcome is, as in many other cancers, 
stage at diagnosis. (4) Table 3 shows that while 84% of patients diagnosed with stage Ia 
or Ib disease are alive 5 years after diagnosis, only 32% of patients diagnosed with stage 
III or IV disease live longer than 5 years after diagnosis.  
For patients diagnosed with advanced disease (stage III or IV) surgery outcome is the 
most important prognostic factor: a completely resected tumor means a considerably 
 
8 The percentages of how much HGSC patients have a BRCA1/2 germline or somatic mutation or another 
HRD differ somewhat in different sources, e.g. Coleman et al. write of approximately  15% germline and 





better prognosis. However, the WHO report from 2014 states: “It is not clear at this time 
whether resectability reflects an intrinsically more favorable disease type, or whether 
increased surgical effort leads to better outcomes independent of intrinsic tumor 
characteristics.” This leads to the highly debated question about whether an aggressive 
surgical approach is justified. Horowitz et al. studied the relationship between disease 
burden before surgery, the complexity of surgery, and residual tumor size. They 
conclude that “more aggressive surgery may be warranted if R0 can be achieved”, but 
also point out that morbidity and mortality resulting from surgery should be considered. 
They also found that disease burden prior to surgery was a significant prognostic factor. 
(35)9 
Table 3: Overall survival of HGSC patients according to stage, data from Peres et al.’ study with 





1 year 5 years 10 years 
Localized = 4,9% of patients 
(corresponds to FIGO IA, IB, I-NOS) 
96.8  84.0 67.5 
Regional = 17,1% of patients 
(FIGO IC, IIA, IIB, IIC, II-NOS) 
93.7 67.7 48.8 
Distant = 77,9% of patients 
(FIGO IIIA, IIIB, IIIC, III-NOS, IV) 
84.3 32.1 15.0 
 
 
Rose and colleagues studied prognostic factors for survival in patients with relapsed 
advanced-stage (stage III or IV) high-grade ovarian carcinoma10. Time to relapse after 
primary surgery and chemotherapy (paclitaxel and platinum) accounted for the major 
part of the prognostic information in their model predicting overall survival after 
relapse. Also performance status and age were significant factors in their model, but 
accounting for much less of the predictive information. (36) Lower performance status 
and higher age have been found previously to be independent predictors of outcome 
(progression free survival and overall survival), e.g. in a study with patients with FIGO 
 
9 This study included cases of advanced epithelial ovarian cancer as well as primary peritoneal cancer, so 
it was not specific for HGSC.  
10 Their study was not specific for high-grade serous ovarian carcinoma, it included also patients with 
endometrioid, clear cell, mucinous or mixed subtype, but all patients had high-grade disease. 81.2% of 




stage III epithelial ovarian cancer (37). The progression free survival after initial 
platinum-therapy as the important prognostic factor for response to second-line 
treatment was identified about 30 years ago (36).   
The response to neoadjuvant chemotherapy was also studied and its use as a prognostic 
factor in HGSC evaluated. Böhm et al. developed a system to quantify response to 
neoadjuvant chemotherapy in histological samples of the omentum and adnexa from 
interval debulking surgery (38).  In this so-called CRS (Chemotherapy Response Score) 
system, a CRS score of 1 means “no or minimal tumor response”; 2 means “appreciable 
tumor response with residual tumor”; and 3 stands for “complete or near-complete 
response” (for a more detailed description of the three categories and training 
possibilities see (39)). Ditzel and colleagues found that the CRS score could be useful as 
a prognostic tool for HGSC. In their study, most notable was the difference between 
scores 1 and 2 as compared to score 3 with regard to outcome (progression free survival 
as well as overall survival); patients scored as CRS 3 had a better outcome. (40) 
Feigenberg and colleagues present findings to suggest that HGSC patients with low-
volume ascites at the time of up-front cytoreductive surgery differ from those with high-
volume ascites, in that they have better clinical outcomes, their immune related genes 
are upregulated, and they have more tumor infiltrating cells (41). 
There are no prognostic tissue markers that can predict response to chemotherapy or 
disease course yet in clinical use, and one major aim for creating this cohort is to validate 
potential markers. 
 
3 Aims of research 
The aims of the research project were to: 
1) create a retrospective cohort of HGSC patients treated at the Helsinki University 
Hospital (HUS) with tissue samples and clinical follow-up data, which can be used 
for the study of different research questions, e.g. response and resistance in 
platinum-based chemotherapy. This cohort can also be provided to collaborating 




2) divide the cohort into different outcome groups and study disease trajectories 
3) search for clinical information that can predict the disease course and outcome  
Progress regarding the first research aim, the process of cohort building, will be covered 
in Chapter 4 on materials and methods. Chapter 5 considers challenges in the collection 
of clinical data and contains a preliminary description of the cohort, and Chapter 6 gives 
an outlook on the next steps in the research projects.  
 
4 Materials and methods 
4.1 Cohort formation based on available tissue samples 
Time frame. Helsinki Biobank holds tissue samples from ovarian cancer (and naturally 
many other) operations performed at the Helsinki University Hospital dating back 
several decades. However, only samples from 1982 on are registered in HUS’s Pathology 
Department electronic database, QPATI; only those samples´ pathology reports are 
accessible and searchable electronically. The Finnish Biobank Act entered into force 
from 1.9.2013. Before that time it was possible for scientists, with permission from the 
hospital ethical board and Valvira, to use biobank tissue samples for research without 
asking the patients for consent or informing them. This changed with the new law and 
now researchers can use tissue samples taken after 1.9.2013 only if patients have at 
some point given their consent for use of their samples for research. However, a general 
consent for inclusion in potential research is rarely requested from patients at the time 
of tissue collection or when undergoing a clinical procedure. To obtain these 
declarations of consent later is a very time-consuming and expensive process. For old 
samples taken before 1.9.2013 an “opt-out” procedure is valid, i.e. individuals have the 
option to actively object to the use of their samples for research, which only a tiny 
fraction of patients do. Because of these practical considerations, and also to study 
overall survival, the period 1.1.1982 – 31.8.2013 was chosen for the creation of the 
cohort, meaning that the patients’ tissue samples were taken during that time. The 




group members. Helsinki Biobank´s scientific-ethical board has given permission to use 
tissue material and associated clinical data from the biobank (approved 28.4.2017).  
Identifying HGSC samples and patients. To identify potential cases for the study cohort, 
the QPATI database was first searched for diagnostic SNOMED 2/3 codes corresponding 
to serous carcinoma (M8461*), unspecified carcinoma (M8010*) independent of growth 
disposition and unspecified poorly differentiated carcinomas (M80203) in the time span 
1.1.1982-31.8.2013, which led to 38,000 hits. Exclusion of patients with only cytology 
samples reduced the number to 34,000 samples, and after filtering for the relevant 
anatomic sites (ovaries, adnexa, uterus, fallopian tubes, omentum and peritoneum), 
5,700 samples were left. These cases were scanned using a search tool that scored 
freeform diagnosis and diagnosis suffix text for inclusion. As pointed out previously, the 
definition of and diagnostic criteria for high-grade serous ovarian carcinoma have 
changed over time, so it was not sufficient to search for the HGSC diagnosis alone. 
Inclusion criteria were, for example, serous carcinoma, carcinoma serosum, HGSC, high-
grade, grade 2, grade 3, gradus II-III, G2, G3, male differentiale, and so on. Exclusion 
criteria were, for example, low grade, gradus 1, and G1.11 
 
Figure 1: Process of identifying patients for the cohort 
 
11 These were exclusion and inclusion criteria at the level of samples. The identification of a “high-grade” 
sample led to the inclusion of the correspondent patient into the cohort, whereas the identification of a 
“low grade” sample did not lead to the exclusion of the patient from the cohort, but to the exclusion of 
the sample from the samples to screen, because it would be possible that another sample of the same 
patient would be “high-grade”.  
923 patients with 2463 samples identified: 
518 cases regarded as HGSOC with high probability, 405 "unsures" 
approx. 350 patients identified by algorithm approx. 650 patients identified by clinician
exclusion of samples with very low scores --> 2,300 samples
taskbuild freesearch tool scored freeform diagnosis and diagnosis suffix text for inclusion 
and exclusion --> 3,000 samples
relevant gynecological anatomy --> 5,700 samples
without cytological samples --> 34,000 samples




After this step 3,000 samples were left. Those 3,000 samples were scored with the aim 
of identifying HGSC samples. Samples with very low scores, e.g. those which included 
only the phrase “male differentiatum”, were excluded. Further, all samples from men 
were excluded. Of the remaining 2,300 samples, about 350 patients with a high-
probability true HGSC diagnosis were detected by keywords, such as “high-grade” and 
“serous carcinoma”. The rest of the samples were evaluated by MD Anniina Färkkilä, via 
identifying key words or sentences from pathology reports, both via excluding e.g. 
tumors of other origin (gastric, pancreas), and by positive key-words (e.g. “high”) and 
reading through the individual pathology reports. This step identified about 650 more 
candidate samples. In total, samples from 923 patients were identified; 518 were 
regarded as having a high probability of being HGSC, and 405 were “uncertain” cases. 
Each patient had one to four tissue samples from different time points and/or different 
tumor sites available in the biobank, so in total, 2,463 samples were identified. 
Confirmation of diagnoses. As the cohort still contains many uncertain cases, and also 
because of changes in the classification and diagnosis of ovarian cancer, the next step is 
to verify diagnoses and include only patients with a confirmed histologic diagnosis of 
HGSC. In a first confirmation step, pathologists Anni Virtanen and Anna Laury re-
evaluate the morphology of the tumor samples and exclude cases which are not HGCS. 
This review process is ongoing on at the time of writing this report12: of the 405 
“uncertain” cases, thus far 51 have been included and 61 excluded13; of the 518 
“relatively certain” cases 262 cases were checked, of which 215 were included and 47 
excluded.  As a second confirmation step, IHC staining for p53 and WT1 will be done on 
all samples that are eventually included as part of a TMA (see TMA formation below).  
4.2 Addition of clinical data to the cohort using electronic data bases and 
paper archives  
The next step was collection of clinical data for the patients included in the cohort. Data 
scientist Jani Salmi was responsible for collecting the necessary information from 
electronic databases of the Helsinki University hospital (DigPhen-project). Clinical data, 
 
12 The following numbers are from October 2019.   





such as comorbidities (as determined by the patients’ ICD10 diagnosis codes six months 
before as well as one year after the diagnosis of HGSC), measurements of CA-125 tumor 
marker levels, other blood analyses, and medications received, were obtained from 
electronic health records of the Helsinki University hospital. 
Survival information, i.e. date of death and cause of death were obtained from Statistics 
Finland for deceased patients. At the time of writing this report, information on the 
death of patients is available only through the year 2015. The information about deaths 
occurring from 2016-2018 has been requested and will be included once delivered. This 
means that for the moment, we can study the 5-year-overall survival only for cases 
diagnosed in 2010 or earlier.  
As some of the necessary data, particularly information concerning surgery and 
chemotherapy treatment, were not easily available electronically, these had to be 
collected from the paper archives. One challenge of clinical data collection in general, 
but especially when it is collected “by hand” from archived paper files, is to decide which 
kind of information to include in the study cohort data pool and in how much detail. The 
goal is to collect as much detailed information as is necessary, while keeping the data 
set as compact as possible in order to not make it a too time-consuming process.  The 
decision regarding which data to obtain from the paper files was made in cooperation 
with gynecologists Taru Tuomi and Mikko Loukovaara, data scientist Jani Salmi, and 
pathologist Olli Carpén. 
The following data was obtained from or calculated based on the information from the 
paper archive of the Helsinki Women’s Hospital (see also data collection sheet in 
appendix):  
- patient baseline age, weight, height 
- date of diagnosis 
- ASA performance grade at first surgery 
- disease stage: FIGO stage as stated in the files, calculation of revised stage 
according to the FIGO 2014 criteria where necessary on the basis of information 




- information on surgical treatment: date, surgery type (debulking, diagnostic, 
inoperable), timing (primary, interval), residual disease (coded according to the 
R0, R1, R2-system, where R0 means no residual macroscopic tumor, R1 stands 
for residual tumor smaller than 1cm in diameter and R2 means a residual tumor 
of 1cm or more in diameter, this is a common categorization, see for example 
(42)) 
- main surgery: As some of the patients were operated more than once, for every 
patient the main surgery of the first treatment line, e.g. the staging surgery if the 
patient had such, was identified based on the collected information on surgical 
treatment. The main surgery type was classified into three categories: primary 
debulking surgery, interval surgery after neo-adjuvant chemotherapy, or a 
primary surgery that is hard to define (e.g. primary inoperable/diagnostic). The 
last class includes cases with only diagnostic surgery in the first treatment line, 
and cases with attempted debulking but (partly) inoperable tumor, or 
emergency surgery with some degree of debulking, etc. The distinction between 
inoperable and suboptimal debulking was not clear in every case (see chapter 
5.1). 
- chemotherapy: dates and doses of each medication for the first three lines of 
treatment as well as first and last date and number of cycles for possible more 
treatment lines 
Progress of clinical data collection: Data collection from the electronic data sources was 
done by data scientist Jani Salmi. It turned out that there was much more data available 
for newer cases, e.g. comorbidity data was available from 2005 on. For this reason, data 
collection from the paper archives started with the cases whose samples were taken 
after 1.1.2005. Of the 923 cases, 687 had samples taken after 1.1.200514. Gynecologist 
Taru Tuomi started data collection from the archived paper files in the spring of 2018 
 
14 As the study time frame ended 31.8.2013 this means on average about 80 patients per year, which is 
close to the estimated 100 HGSC patients treated in HUS every year. However, for the time 1.1.1982 – 
1.1.2005 the search identified much less cases per year, which might be due to the fact that the 
treatment of HGSC or ovarian cancer in general was not done centralized in HUS hospital during the 
whole time frame. Another explanation could be that the search algorithm identified newer samples 




and collected information from 115 cases; I collected information from approximately 
500 additional cases during summer 2018 and summer 2019.   
The status of data collection from the paper archives at the time of writing this report is 
as follows (see also Figure 2): 113 of the 687 cases, for which paper files were ordered 
to the archive, have been excluded thus far. Cases were excluded due to information 
found in the paper files (no chemotherapy received, a non-high-grade serous diagnosis), 
or following the pathologists’ screening of the tumor samples slides (not enough tissue, 
diagnosis other than HGSC). Patients who did not receive chemotherapy, usually very 
old patients with considerable comorbidities, were excluded from the cohort because 
one key goal of this project is to study tumor response and resistance to platinum-based 
chemotherapy. Clinical data has been collected for 516 cases, of which 320 now have 
complete information. For the remaining 196 cases, some data has been collected 
(usually surgery information), but part of the information is incomplete (usually 
chemotherapy information). There are three different reasons why the clinical 
information collection is not yet completed:  
- Firstly, in 62 cases the patient came to the HUS hospital for surgery only and had 
chemotherapy at her home hospital, from which we do not (yet) have the 
corresponding information.  
- Secondly, papers containing chemotherapy information or other clinical data 
were missing from the files (52 cases). For example, files for a patient with an 
active relapse at the time of data collection would be in use at the hospital and 
would therefore not be accessible in the archive. In addition, the type of data 
storage changed over time; from 2014 on, printouts of the patients’ care reports 
were no longer included in the paper files, and the type of documentation for 
chemotherapy dates and dosages changed from handwritten forms to digital 
forms over the last years. 
- Thirdly, detailed information about the chemotherapy is missing for a few cases 
due to a change in our data collection protocol (80 cases).  
The research group has to decide which of the missing information is important to 
obtain. This could be accomplished by assessing the files again, searching for the missing 
documents, or requesting cooperation from the patients’ home hospitals. One 
possibility is also that some of the clinical information is available only for some patients 
in the cohort and depending on the analyses one wants to conduct, one chooses the 




There are 35 cases for which data has not been collected yet, partly because their papers 
were not provided by the archive, and partly because of time constraints.  
Figure 2: Clinical data collection from paper archives (status as of 12.10.2019) 
4.3 Tissue samples and TMA formation  
In order to test our research procedures, verify diagnoses and do preliminary testing for 
novel biological markers, an initial TMA consisting of tissue samples from 109 patients 
was constructed. For this first TMA, patients were selected according to the following 
criteria: they had received primary debulking surgery with tissue samples available from 
this surgery (this tissue was used for the TMA), they had stage III or IV disease at 
diagnosis, the HGSC diagnosis had been morphologically confirmed by a pathologist, 
they had received at least 6 cycles of platinum-taxane based chemotherapy following 
surgery and finally, they had a biochemically complete treatment response, meaning 
that the CA-125 value dropped below the threshold of 35 U/ml after starting treatment. 
This group contains patients with very different progression times, meaning the time 
after the end of the first chemotherapy treatment line to progression (as measured by 
a CA-125 value over 35 U/ml). The progression time ranged from 0 months, i.e. response 
after beginning of treatment but progression already before the end of the first 
treatment line, to over 18 months.  
As a first step, immunohistochemical staining for HGSC diagnosis verification was 
performed: aberrant TP53 and positive WT1 staining served as diagnostic criteria.  
In the future, more TMAs are planned, e.g. those containing subsequent tissue samples 
from the patients in the first TMA, for those cases that such tumor tissue is available 
from later surgery or biopsies. Also, a TMA comparing pre-surgery and interval surgery 
923 cases (518 HGSC with high probability & 405 "unsures") 
687 cases with identifying sample taken 2005-2013
--> paper files ordered to Iiris-archive
320 cases with 
data collection 
completed
196 cases with missing 
information: 62 due to 
chemotherapy in other 
hospital, 115  due to 








21 cases --> 
unclear, needs 
clarification
236 cases with id. 
sample taken 





tissue samples will be interesting. In the end, the goal is to have tissue samples from all 
patients included in the study available in at least one TMA.  
5 Results 
As outlined in chapter 3 the aim of this report and research was to 
- divide the cohort into different outcome groups and study disease trajectories 
- search for clinical information that can predict course of disease and outcome  
However, building the cohort took longer than originally planned and is not yet 
completed. A considerable proportion of the needed information, such as elements of 
the chemotherapy information, and the information on deaths for the years 2016-2018, 
is still missing. The confirmation of diagnoses by pathologists, and with that the inclusion 
of patients to the final study cohort, is still ongoing. Therefore, data analysis is not yet 
possible. Hence this chapter will first point out challenges in the clinical data collection 
and then give a preliminary description of some characteristics of the study cohort thus 
far.  
 
5.1 Challenges in clinical data collection 
It was challenging in some cases to classify certain information obtained from the 
archived files. For instance, identification of the surgery type was not always 
straightforward, e.g. to distinguish a primary debulking surgery from a primary 
diagnostic/inoperable surgery in a case where debulking had been attempted (and 
tumor mass was debulked to some degree) but the surgery report states that no further 
surgical measures are possible, and a substantial tumor mass remains. Consequently, 
the distinction between a surgery classified as “inoperable” (i.e. “hard to define”) and 
one classified as “debulking with residual tumor = R2” was in some cases too difficult to 
resolve and consequently this classification of the cases is not reliable. Future users of 
the data should be aware of this and the categorization should be revised and/ or 




In contrast, information regarding whether the surgery took place before chemotherapy 
(primary surgery) or after chemotherapy (interval surgery) was readily available. 
Information about residual tumor size after surgery was clearly stated in some reports, 
but in others it was described only as “carcinosis” or “small lumps” of tumor, so the 
classification in terms of R1 vs R2 was not always straightforward. We classified residual 
tumor described as “carcinosis” as R2, unless it was clear from the description that it 
was less than 1 cm in diameter. In contrast, to distinguish an R0 result from surgery with 
some kind of residual tumor was easy, since complete cytoreduction was typically clearly 
stated in the surgical reports. The conclusion for future data users is that only the 
distinction between R0 and any other R (i.e. R1, R1-2, R2) is reliable.  During data 
collection it also became evident that the R2 residual tumor class encompasses a wide 
variety of surgical outcomes. R2 disease ranges from one small tumor mass with a 
diameter of 1 cm, to thick carcinosis throughout the abdominal cavity, to a residual 
tumor measuring 15 cm or more. It would be informative to have a more precise 
measure for residual tumor. The inclusion of additional data, e.g. imaging data, could 
help. Another improvement could be to collect the pattern of residual tumor, e.g. how 
many patients present with carcinosis spread to a wide area.  
Another observation was that the numbering of the treatment lines (first line, second 
line) as recorded in the archived files was not always uniform: sometimes a change of 
medication during a treatment line, i.e. because of allergy to paclitaxel, led to a new 
treatment line designation, while in other cases the treatment line number stayed the 
same, and the medication simply changed. As a result, the number of treatment lines as 
documented in the files is not necessarily a good measure of how many chemotherapy 
doses a patient has received. 
 
5.2 Preliminary analysis of the cohort 
The following descriptions refer to the cohort as of 10.10.2019, i.e. the cases for which 
clinical data were collected and which have not been excluded so far. This includes 516 
cases (as described in chapter 4.2.); 320 cases with data collection completed plus the 




lacking. However, it is possible that some cases may still be excluded based on the 
pathologists’ morphologic screening or the IHC staining, or that the surgery classification 
will be revised. 
 
Figure 3: Number of cases according to FIGO disease stage and availability of 5-year survival 
information (n=513, 3 cases with missing information on stage) 
When looking at 5-year overall survival, 317 of the 516 cases can be evaluated because 
they were diagnosed in 2010 or earlier, as information regarding patient deaths is 
currently available up to 2015. When looking only at the patients with spread of the 
disease outside the pelvis, i.e. stages III and IV, the numbers are 444 cases in total, with 
285 cases diagnosed 2010 or earlier. Figure 3 gives an overview of the different groups 
used for the following preliminary descriptive analyses. The number of cases used in a 
certain graph can be somewhat smaller if there are missing values for the variable 
studied, i.e. if some information was not available in the papers assessed. 
Similar to findings in other studies, most of the patients in our cohort presented with 
advanced stage disease. 86.5% of them were stage III or IV at diagnosis, with stage IIIc 
being the most frequent stage (57.9% of patients). For comparison, a study from Peres 





Cases of the following preliminary analyses according to 
FIGO disease stage and availability of 5-year survival data
stage I & II, 5 year survival evaluable stage III & IV, 5 year survival evaluable
stage III & IV, 5 year survival not evaluable stage I & II, 5 year survival not evaluable
stage III & IV
cases with stage III & 
IV are 159 + 285 = 444 
cases
5 year survival 
evaluable for 32 + 285 = 
317 cases 




III or IV and 22% with stage I or II (12). Table 4 presents the frequencies of different 
disease stages at diagnosis in our preliminary sample15. 
Table 4: Patients’ FIGO disease stage at diagnosis, n=51316 
 
Stage at diagnosis according to FIGO 2014 Frequency Percent 
Stage I 
1a 11 2.1 
7,0 % 
1b 2 .4 
1c 1 .2 
1c1 7 1.4 
1c2 3 .6 
1c3 11 2.1 
1 NOS 1 .2 
Stage II 
2a 17 3.3 
6,4 % 
2b 16 3.1 
Stage III 
3a1 17 3.3 
67,6 % 
3a2 6 1.2 
3b 26 5.1 
3c 297 57.9 
3 NOS 1 .2 
Stage IV 
4a 33 6.4 
18,9 % 4b 62 12.1 
4 NOS 2 .4 
Total  513 100.0 % 
 
The mean age of patients at diagnosis was 64.3 years (SD 9.7 years); the youngest 
patient being 34 years old at the time of diagnosis and the oldest 87. Figure 4 shows the 
distribution of patients’ age at diagnosis, showing that most of the patients were 
between 60 and 70. The mean age was about the same when patients were grouped 
according to their disease stage at diagnosis (see table 5). 
 
Table 5: Mean age at diagnosis by disease stage   
FIGO stage Mean age at diagnosis n sd 
I 64.9 yrs 36 10.1 
II 62.9 yrs 33 11.4 
III 64.5 yrs 347 9.8 
IV 64.0 yrs 97 9.0 




15 IBM SPSS Statistics 25 software was used for all analyses.  





Figure 4: Distribution of patients’ age at diagnosis 
 
Similar to findings in other studies the 5-year overall survival is clearly higher in patients 
with stage I or II disease as compared to stage III and IV disease, e.g. 78.6% of patients 
with disease stage I were alive after 5 years compared with 16.7% of patients with stage 
IV disease (see table 6).  
Table 6: 1-year and 5-years overall survival in patients grouped by FIGO disease stage at 
diagnosis (Chi-Square-Test for differences between stage groups significant for 5-year-overall 
survival) 
FIGO stage OS 1 year OS 5 years 
 I  100.0% (n=14) 78.6% (n=11) 
II  100.0% (n=18) 72.2% (n=13) 
III  95.0% (n=208) 32.0% (n=70) 
IV  100.0% (n=66) 16.7% (n=11) 
Total  96.5% (n=306) 33.1% (n=105) 
 
 
Comparing the mean age at diagnosis of those patients who are alive 5 years after 
diagnosis and those who are not, one finds a significant, but possibly not very important, 
difference: Those alive after 5 years are slightly younger (61.6 vs. 64.7 years, mean; t-
test for independent samples significant (2-tailed) p <0.05) – a preliminary finding that 





Table 7: 5-year overall survival according to performance status (ASA-class), n= 30817, Chi-
Square test significant p<0,05 
Performance status 5-year OS 
ASA1, 2 or 2-3 42.2% (n=54) 
ASA3, 4 or 3-4 27.2% (n=49) 
Total 33.4% (n=103) 
 
Performance status seems to have prognostic value as well, which was also noted in 
other studies (see chapter 2.8). Looking at all disease stages together, 42.2% of patients 
with ASA class 1, 2 or 2-3 were alive 5 years after diagnosis, compared with 27.2% of 
patients with ASA class 3, 4 or 3-4 (see table 7). 
The distribution of the main surgery type is displayed in table 8. 60.5% of cases had 
primary debulking surgery as the main surgery, 20.2% an interval surgery, and in 19.3% 
the primary surgery type was hard to define. When analyzing only cases with stage III or 
IV disease, the percentage of interval surgery is somewhat higher and the percentage of 
primary debulking surgery somewhat less, which is due to the fact that nearly all patients 
with stage I or II disease are able to undergo primary debulking surgery (see table 8).  
Table 8: Distribution of main surgery type18  
Type of main surgery  all stages only stages III & IV 
interval surgery 103 (20.2%) 97 (22.1%) 
primary debulking surgery 308 (60.5%) 246 (56.0%) 
primary surgery that is hard to define 98 (19.3%) 96 (21.9%) 
Total 509 (100%) 439 (100.0%) 
 
Regarding residual disease at the conclusion of the main surgery, 30.3% of the 
preliminary cohort patients had a complete cytoreduction (R0), 10.9% had residual 
disease measuring less than 1 cm diameter (R1), and 58.8% had residual disease greater 
than 1 cm (R2, see table 9). As mentioned previously, the distinction between R1 and R2 
was not always possible with the available records, so one can only reliably distinguish 
 
17 There were 9 cases with no information on ASA class, therefore n=308 
18 for all stages n= 509, 7 cases with information on main surgery type missing, and for stage III & IV only 




between R0 and non-R0 in this dataset. When looking at the cases with stage III or IV 
disease, the percentage of patients with complete cytoreductions drops to about 20% 
because R0 is much more likely in a patient with stage I or II disease (see table 9).  
Table 9: Distribution of residual disease after main surgery in the first treatment line19  
Residual tumor  all stages only stages III & IV 
R0 153 (30.3%) 89 (20.5%) 
R1 55 (10.9%) 52 (12.0%) 
R2 (including R1-2) 297 (58.8%) 293 (67.5%) 
Total 505 (100.0%) 434 (100.0%) 
 
When looking at the residual disease by surgery type, it seems that a larger percentage 
of interval surgeries had an optimal result, i.e. R0, as compared to primary debulking 
cases (46.0% vs 34.2% across all stages and 43.6% vs. 19.6.% for stages III & IV, see tables 
10 and 11).  
Table 10: Distribution of residual disease according to different main surgery types for all 
stages20 
Main surgery type R0 R1 R2 & R1-2 Total 
 interval surgery 46.0% (n=46) 26.0% (n=26) 28.0% (n=28) 100.0% (n=100) 
primary debulking surgery 34.2% (n=105) 9.1% (n=28) 56.7% (n=174) 100.0% (n=307) 
primary hard to define 1.0% (n=1) 1.0% (n=1) 97.9% (n=94) 100.0% (n=96) 
Total 30.2% (n=152) 10.9% (n=55) 58.8% (n=296) 100.0% (n=503) 
 
This could be due to the fact, that NACT reduces tumor size and the tumor is then easier 
to resect. Another explanation for this difference could be that the pre-operative 
determination of the likelihood of achieving an optimal cytoreduction influenced the 
decision to do an interval surgery21 more than it influenced the decision to undertake a 
 
19 for all stages n= 505, 11 cases with missing information on tumor residual; and for only stages III & IV 
n=434, 10 cases with missing information on residual tumor 
20 n = 503, 13 cases with missing information on main surgery type and/or residual tumor size 
21 For example patients treated with NACT, whose tumor did not shrink in response to the treatment, 
might not have had an interval surgery. So those patients would have the primary diagnostic surgery as 
their “main surgery type”, which would be classified as “primary hard to define” in this study. Or for 
patients, that did not have surgical treatment at all, i.e. patients, who did not have primary diagnostic 
surgery, and interval surgery was planned but not done because of the tumor not responding to the 
neo-adjuvant chemotherapy; these patients would not be included in our cohort, because one criteria 




primary debulking surgery. Also the difficulties with classifying patients’ surgery type, 
i.e. the difficulty to distinguish primary debulking and primary hard to define, influence 
the results. In general, the changing surgical treatment protocol over the time span of 
the study cohort also influences the results. 
Table 11: Distribution of residual disease by main surgery type for patients with stage III or IV 
disease22 
Main surgery type R0 R1 R2 & R1-2 Total 
interval surgery 43.6% (n=41) 27.7% (n=26) 28.7% (n=27) 100.0% (n=94) 
primary debulking surgery 19.6% (n=48) 10.2% (n=25) 70.2% (n=172) 100.0% (n=245) 
primary hard to define 0.0% (n=0) 1.1% (n=1) 98.9% (n=93) 100.0% (n=94) 
Total  20.6% (n=89) 12.0% (n=52) 67.4% (n=292) 100.0% (n=433) 
 
When comparing 5-year overall survival between patients according to their surgical 
outcome, the more favorable outcome of patients with complete cytoreduction 
compared to patients with a residual tumor of R1 or R2 seems evident (61.3% compared 
to 27.8% and 23.1.% across all stages and 51,9% compared to 25.7% and 22,8% for 
stages III & IV, see table 12). This is in congruence with earlier research findings 
mentioned in chapter 2.8.  
Table 12: 5-year overall survival by residual tumor amount23  
Residual tumor 5-year OS, all stages 5-year OS, stages III & IV 
 R0 61.3% (n=49) 51.9% (n=27) 
R1 27.8% (n=10) 25.7% (n=9) 
R2 23.1% (n=45) 22.8% (n=44) 
Total 33.2% (n=104) 28.6% (n=80) 
 
When comparing the outcome of patients with the different types of major surgery, the 
5-year overall survival is higher in the primary debulking group as compared to the 
 
22n = 433; 11 cases with missing information on main surgery type and/or residual tumor size, Chi-
square test significant p<0.05 
23 for all stages: 6 cases with missing information on residual tumor, Chi-square test significant p<0,05; 
for only cases with stage III or IV disease: 5 cases with missing information on residual tumor, Chi-square 




interval surgery group (41.2% vs. 29.5.% for all stages and 35.2% vs. 28.3% for stages III 
and IV, see table 13). When comparing 5-year overall survival in patients with advanced 
disease and surgical outcome R0 there is no statistical significant difference between 
the primary debulked group and the interval surgery group (48.3% vs. 56.5%, see table 
14), however the sample might be too small to show a possible difference. 
 
Table 13: 5-year overall survival according to major surgery type24  
Main surgery type 5-year OS, all stages 5-year OS, stages III & IV 
interval surgery 29.5% (n=18) 28.3% (n=17) 
primary debulking 41.2% (n=80) 35.2% (n=58) 
primary hard to define 8.8% (n=5) 8.8% (n=5) 
Total 33.0% (n=103) 28.4% (n=80) 
 
However, one cannot draw conclusions regarding the question of whether a primary or 
interval surgery is better in general, because the patients in the primary debulking group 
were more likely to be patients with tumor that was resectable, which could mean that 
their disease had a better prognosis regardless of the timing of their surgery (see 
discussion on surgery types in chapter 2.8). 
Table 14: 5-year overall survival according to major surgery type for patients with stage III or 
stage IV disease AND residual tumor of R0, Chi-square test not significant, p>0.05. 
 5-year overall survival 
 stage III or IV & interval surgery & R0  48.3% (n=14) 
stage III or IV & primary debulking & R0  56.5% (n=13) 
 
One goal of building the cohort was to divide patients into different outcome groups 
and try to find explanations for patients´ very different disease trajectories. Figure 5, 
which Jani Salmi kindly provided from his presentation, shows, that the collected data 
can be used to study disease trajectories on the level of the individual patient. While the 
three patients had similar performance status, stage and first line chemotherapy, their 
 
24 for all stages: 5 cases with missing information on major surgery type, Chi-square test significant 
p<0.05, and for only cases with stage III or IV disease: 3 cases with missing information on major surgery 




outcomes are still very different. The picture demonstrates the considerable difference 
in survival between patients, which could be due to biological differences in patients` 
carcinomas25. Further research with this cohort, once it is ready, will try to find such 
biological differences.   
 
Figure 5: Disease trajectories of three patients with same performance status, stage and first 
line chemotherapy treatment but different outcomes, picture from Jani Salmi 
 
6 Conclusions and prospects 
High-grade serous ovarian cancer is an important and interesting disease to study. 
Chapter 2 introduced the topic and gave an overview of the research findings in this 
field. Despite progress in the understanding of the underlying biological processes, the 
prognosis of patients has not improved significantly during the last decades, though the 
new PARP-inhibitors might be about to change this.  
The primary goal of the research project covered in this report is to create a 
retrospective cohort of HGSC patients with tissue samples and clinical follow-up data, 
which can be used to study different research questions (for example studying the 
response and resistance to platinum-based chemotherapy) and can also be provided to 
 
25 The younger age of patient A could indicate the higher possibility of a BRCA-mutation. This will have 
to be checked. The BRCA-mutation is one of the very few, if not the only, known biological marker in 
HGSC, that is used in the clinic with consequences for the choice of the treatment, e.g. the application of 




collaborating research groups, such as for the testing of potential biomarkers. The 
current status of the cohort formation was described in chapter 4. There were initially 
over 900 patients identified as potential cases for inclusion in the cohort. The process of 
confirming diagnoses and other requirements (i.e. only patients who received surgical 
and chemotherapeutic treatment are included) is ongoing. There were some challenges 
with the collection and categorization of clinical data, such as with the characterization 
of the surgery type. These challenges were discussed in chapters 4 and 5. Important 
information on potential problems with some of the collected clinical information has 
been added to the description in the appendix, so that future users of the dataset can 
understand the nature and limitations of the data.  
The second and third research aims, as stated in chapter 3, were to divide the cohort 
into different outcome groups and study disease trajectories in order to search for 
clinical information that may predict the disease course and patient outcome. Because 
the cohort building took more time than was planned and is not yet complete, chapter 
5 presents only some preliminary descriptions of the cohort. These descriptions seem 
to be in concordance with other research findings, e.g. patients with lower disease stage 
(stage I and II) had a considerably better 5-year overall survival than patients with 
disease stages III or IV at diagnosis; the distribution of disease stages was similar to other 
studies. Additionally, patients with complete cytoreduction (R0) had a better prognosis. 
These preliminary findings are reassuring; the cohort will be an appropriate group of 
patients in which to study the disease.   
The next steps in the cohort formation will be to complete the diagnosis confirmation 
and clinical data collection for those cases which were not assessed, e.g. the cases with 
the diagnostic samples taken before 2005. Then the research team needs to decide 
which missing information to continue to search for (see chapter 3). Another step will 
be to begin analyzing the chemotherapy information; data scientist Jani Salmi has 
started working on this. It is also planned to study progression free survival; for now, the 
CA-125 levels are used to identify relapses. However, additional reports, such as 
radiology information, will need to be assessed in some patients in order to reliably 




In addition, the cohort will be used by other researchers and research groups. Cyclin E 
expression will be analyzed by biologist Noora Andersson using RNA in-situ-
hybridization as well as standard immunohistochemistry. Both techniques are being 
used in order to validate the relatively novel RNA in-situ-hybridization technique. The 
research question here is whether cyclin E expression is increased in patients with 
shorter progression free survival. Further, it is planned to test additional markers using 
this same TMA, e.g. Liisa Kauppi´s group will stain the TMA for cytokeratin 7 expression 
to distinguish tumor cells from stroma cells and then evaluate gamma-H2AX expression, 
which is a new marker of DNA double-strand breaks. Also, expression of fusion proteins 
such as MLL1 will be tested. Pathologist Anna Laury will also use the TMA in her project 
involving image analysis of histological slides.   
To conclude, the building of such a large cohort comprising both tissues samples and a 
large amount of clinical information, which comes from various electronic databases as 
well as from archived paper files, is a long process. Despite modern technologies to 
gather large amounts of data, bottlenecks remain. For instance, knowledge of the 
reporting practices as well as clinical expertise both in gynecological oncology and in 
pathology are vital for the successful execution of such a project. Diagnostic criteria and 
clinical recommendations on surgery and chemotherapy evolve over time, which poses 
a challenge for dissecting the role of biological characteristics in the disease outcome. 
However, as a conclusion, the Finnish biobank infrastructure, electronic medical record 
system and legislation provide unique opportunities for collection of cohorts combining 
clinical information and biological specimens. Once the cohort is ready it will be a unique 
and invaluable tool for studying diverse research questions in the field of high-grade 
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Description of clinical data collected from paper archives 
The following information in Finnish was used as a guide for the collection of clinical data 
from archived paper files.  
 
1. Tarkista diagnoosi  
 
Tavoitteena on, että kohortti rajoittuisi ovario-, tuuba- tai peritoneum-peräisiin high-grade 
serooseihin syöpiin (HGSC). Ei kerätä tietoja, jos diagnoosi on muu epiteelimunasarjasyöpä kuin 
seroosi (esim. Ca endometrioides, kirkassoluinen jne.) tai jos kyseessä on vanhan diagnostiikan 
mukaiset seroosit G1 karsinoomat. G2 seroosit otetaan mukaan. High-grade mixed type voi tulla 
mukaan (on vanhaa luokittelua, nämä ovat usein high-grade serous), sen sijaan Ca serosum 
endometroides jää pois. 
Kaikki potilaat, joiden osalta päätetään, ettei kerätä tietoja, kirjoitetaan omaan listaan. Heille kuten 
kaikille muillekin patologi tekee tarvittaessa vielä morfologian ja IHC-värjäyksen perusteella 
diagnoosin tarkistuksen.  
 
2. Yleiset tiedot  
 
pvm päivämäärä, jolloin tiedot kirjoitetaan Exceliin 
aika kellonaika, esim. 9:10 - 9:45 
kuka lyhenne henkilöstä, joka kerää tietoja  
 
Potilaan yleiset tiedot  
hetu      
nimi      
dg pvm  päivämäärä, milloin potilas tulee ensimmäistä kertaa poliklinikalle  
(jos sitä ei ole saatavilla, niin esim. ensimmäisen kohonneen CA-125-mittauksen 
päivämäärä tai esim. ensimmäisen leikkauksen päivämäärä, jossa syöpä oli 
sivulöydöksenä etc. tai ensimmäisen kemokuurin päivämäärä jos oli NACT) 
  
paino  paino hoidon alussa: jos paino löytyy ensimmäisen leikkauksen anestesiakaavakkeesta, 
otetaan sieltä, muuten esitiedoista.  
kg  
pituus    cm  
ASA  Jos luokka vaihtelee, otetaan luokka ensimmäisessä leikkauksessa. Jos ensimmäisen 
leikkauksen ASA-luokka ei lue papereissa, otetaan toisen leikkauksen ASA-luokka jos 
sellainen on.  
  




Stage (papereissa) tässä kirjoitetaan stage, joka lukee papereissa  
Uusi stage Jos stagen määritelmä on tehty ennen 2014: luokitellaan stage uuden 2014 FIGO:n 
luokituksen mukaan  
 
Luokittelun uudistus 2014 pitää sisällään 4 asiaa: 
• IC on alaluokiteltu numeroin 1-3 sen mukaan, onko tuumori puhjennut leikkauksessa, ennen 
leikkausta, tai onko askiteksen sytologia positiivinen. Tuumorin puhkeaminen pitäisi olla 
mainittu leikkauskertomuksessa. 
• IIC on kokonaan poistettu (tämä on varmasti harvinainen stage). 
• Stage IIIA on muutettu siten, että siinä on mukana imusolmukkeisiin metastasoineet syövät 




kanssa (IIIA2). Aiemmin imusolmukemetastasointi teki stagen aina IIIC:ksi. Uudistus 
tehtiin sen takia, että isoloituun imusolmukemetastasointiin liittyy parempi ennuste kuin 
vanhaan stage IIIC:hen. Uusi stage IIIA on harvinainen, mutta pitäisi olla jäljitettävissä 
leikkauskertomuksesta ja PAD-lausunnosta. IIIA1(i) ja IIIA1(ii) eivät luultavasti ole aina 
erotettavissa toisistaan, koska erottelu perustuu imusolmukemetastaasin kokoon, jota ei taida 
olla useinkaan mainittu PAD-lausunnossa. 
• IV on saanut alaluokat A (pleura) ja B (maksa, perna, ekstra-abdominaaliset). 
→ Leikkauskertomuksesta ja kuvantamislöydöksistä pitäisi selvitä paikat, missä kasvainta on. 
Kuvantaminen on keskeinen lähinnä stage IV:n toteamisessa. Epikriisissä on tällöin yleensä 
yhteenveto kuvantamislöydöksistä. 
→ Munasarjasyövän, tubakarsinooman ja peritoneaalikarsinoosin staging-luokitus on sama. 
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4. Leikkaukset  
Tässä haetaan tietoja vatsaontelon sisälle tehdyistä leikkauksista, joiden syynä on ollut 
syöpäkudoksen pienentäminen syövän parantamiseksi, tuumorin pienentämiseksi/diagnostiikan 
varmentamiseksi ja levinneisyyden selvittämiseksi. Huom: ei palliatiiviset leikkaukset 
(esim. aivometastaasien leikkaaminen).  
1. leikkaus, pvm    
1.leikkaus, 
tyyppi   
• primary diagnostinen  
• primary debulking 
• primary inoperable/diagnostinen  
• interval debulking  
• interval diagnostinen 
• interval inoperable/diagnostinen  
• muu leikkaus: vastaa primary diagnostinen/inoperable  
• muu leikkaus: vastaa primary debulking 
• debulking: hoidetaan uusiutunut tauti 
• second look 
Leikkaus merkitään interval-leikkaukseksi aina kun se on tehty sytostaattihoidon alkamisen 
jälkeen.  
HUOM:  
- tyyppi inoperable/diagnostinen ei ollut alusta asti mukana, siksi diagnostista tyyppiä ja 
tyyppiä inoperable/diagnostinen ei pysty erottamaan toisistaan. Pelkästään diagnostisia 
leikkauksia oli vähän. 
- primary debulking & R0: on myös laitettu jos on löydetty esim. stage-1-tauti ja silloin 
poistettu vaikka vain munasarjat ja munanjohtimet.  
- erotus inoperable/diagnostinen ja debulking & R2 välillä on ollut välillä erittäin hankalaa, ei 
ole saatu hyvin eroteltua.  
1.leikkaus jäänn
ös  
Jos leikkauksen tarkoitus oli debulking, kirjoitetaan jäännöskasvaimen koko 
(löytyy leikkauskertomuksista)  
• R0 = no residual disease, 
• R1 = minimal residual disease (deposits of residual tumour <1 cm),   
• R2 = gross residual disease (deposits of residual tumour >=1 cm).  
Mitataan yksittäisten kasvainmuutosten läpimitta: Jos jää parikymmentä 0,5 
cm:n tuumoria, kyseessä on R1. Jos taas jää yksi 2 cm:n tuumori, kyseessä 
on R2.  
Leikkauskertomukseen merkityllä jäännöskasvaimen koolla tarkoitetaan 
suurimman pesäkkeen läpimittaa siten, että tämän kokoisia tai tätä pienempiä 
pesäkkeitä voi olla useita. Esim. jos jäännöskasvaimeksi on merkitty 1 cm, 
tämän kokoisia pesäkkeitä voi olla useita, ja lisäksi voi olla pienempiä 
pesäkkeitä.  
Jos ei selvästi kerrota, ovatko jäljelle jäävät kasvaimet R1 vai R2, käytetään 
määritelmää R1-2.  
Jos jäännöskasvaimena on mainittu vain karsinoosi ilman kokoa tai 
mainitaan että karsinoosi on todella pieni, kirjoitetaan R2.  
• R0  
• R1  
• R2  
• (R1-2)  
1.leikkaus 
karsinoosi 
Tänne kirjoitetaan silloin, kun jäännöskasvain on karsinoosi, teksti siitä, 
miten karsinoosi on kuvattu leikkauskertomuksessa (esim. 
”jäännöskasvaimeksi jää laaja karsinoosi”) 
 
HUOM: tämä kategoria ei ollut koko ajan mukana, on ollut välillä mukana 








Vastaavasti muut leikkaukset.  
Myöhemmin lisätty: main surgery 
main_surgery type of the first treatment line → Valitaan jokaiselle potilaalle ensimmäisen 
hoitolinjan „pääleikkaus“, eli jos on tehty staging leikkaus / debulking leikkaus, niin sitten se 
on „pääleikkaus“; jos on vain diagnostinen leikkaus tai inoperable, niin sitten se on 
„pääleikkaus“ —> tämä tehtiin sen takia, että osalla potilaita on enemmän kuin yksi leikkaus 
ensimmäisen hoitolinjan aikana ja kun vertaillaan leikkaustyyppejä, jäännöskasvaimia jne., niin 
tarvitaan per potilas yksi „pääleikkaus“, johon tyyppi, jäännöskasvain jne. viittaa. Eli 
käytännössä katsotaan, mitkä leikaukset potilaalle on tehty ja jos on enemmän kuin yksi, niin 
identifioidaan pääleikkaus ja sitten valitaan yksi seuraavista kolmesta tyypistä:  
- PDS = primary debulking surgery 
o Ei kemoterapiaa ennen leikkausta 
o Voi olla että on ollut diagnostinen leikkaus ennen PDS:ää  
- interval surgery 
o Kemoterapia ennen pääleikkausta: voi olla että kemoterapia ennen leikkausta 
ja sen jälkeen tai vain ennen leikkausta  
o Voi olla että ennen kemoterapiaa on ollut diagnostinen leikkaus  
- primary_hard-to-define 
o Jos pääleikkaus on primaarileikkaus ja esim. diagnostinen/inoperable tai muu 
vastaava 
Pääleikkauksen päivämäärä (date of main surgery) 
Pääleikkauksen jäänöskasvain (residual tumour): R0, R1, R2 
Age at diagnosis: laskettu syntymäpäivämäärän (hetusta) ja diagnoosipäivämäärän erotuksena  
5. Hoitolinjat  
Tässä kerätään tietoa, milloin mitä sytostaattia tai muuta syöpälääkettä on annettu ja millä 
annoksella. Annokset kirjoitetaan karboplatiinilla AUC:na, Avastinille mg/kg:na ja muille 
sytostaateille mg/m2:na. Tarkoitus on, että annoksia voidaan verrata eri potilaiden välillä.  
 
Hoitolinjat 1 – 3 kirjoitetaan tarkemmin, muut hoitolinjat ilman annosta.  
 
Hoitolinjat 1 – 3: Tässä sovittiin, että kirjoitetaan aloitus- ja loppupäivämäärä sekä kaikki annokset.  
 
Hetu Hoitolinja Hoitosykli Pvm 1. Lääkeaine Annos 2. Lääkeaine Annos 3. Lääkeaine Annos 
  
        
 
Hoitolinjat 4 – x  
 
Hetu Hoitolinja Lääkeaine Pvm aloitus Pvm loppu  Kuurien lukumäärä 
  




6. Skannataan  




- Patologiset näytteet -kaavake (leikkausnäytteet) 
